Sumitomo Mitsui DS Asset Management Company Ltd Sells 264 Shares of Humana Inc. (NYSE:HUM)

Sumitomo Mitsui DS Asset Management Company Ltd lowered its position in Humana Inc. (NYSE:HUM) by 1.9% in the 4th quarter, Holdings Channel reports. The fund owned 13,699 shares of the insurance provider’s stock after selling 264 shares during the quarter. Sumitomo Mitsui DS Asset Management Company Ltd’s holdings in Humana were worth $3,476,000 as of its most recent SEC filing.

A number of other institutional investors and hedge funds also recently made changes to their positions in HUM. AMF Tjanstepension AB grew its stake in shares of Humana by 166.8% in the 3rd quarter. AMF Tjanstepension AB now owns 40,051 shares of the insurance provider’s stock worth $12,686,000 after buying an additional 25,041 shares during the last quarter. Livforsakringsbolaget Skandia Omsesidigt increased its holdings in shares of Humana by 49.6% during the third quarter. Livforsakringsbolaget Skandia Omsesidigt now owns 4,827 shares of the insurance provider’s stock valued at $1,532,000 after acquiring an additional 1,600 shares in the last quarter. Gateway Investment Advisers LLC raised its position in shares of Humana by 6.1% in the 3rd quarter. Gateway Investment Advisers LLC now owns 3,112 shares of the insurance provider’s stock worth $986,000 after purchasing an additional 180 shares during the last quarter. Exchange Traded Concepts LLC bought a new position in Humana in the 3rd quarter worth about $348,000. Finally, Koshinski Asset Management Inc. grew its position in Humana by 32.4% during the 3rd quarter. Koshinski Asset Management Inc. now owns 1,499 shares of the insurance provider’s stock valued at $475,000 after purchasing an additional 367 shares during the last quarter. Hedge funds and other institutional investors own 92.38% of the company’s stock.

Analyst Ratings Changes

Several research analysts have recently issued reports on the stock. Barclays upped their target price on shares of Humana from $253.00 to $255.00 and gave the stock an “equal weight” rating in a research note on Wednesday, January 22nd. TD Cowen lifted their target price on Humana from $261.00 to $268.00 and gave the stock a “hold” rating in a report on Monday, November 4th. Bank of America raised Humana from an “underperform” rating to a “neutral” rating and upped their price target for the company from $247.00 to $308.00 in a report on Wednesday, November 6th. Morgan Stanley lifted their price objective on Humana from $288.00 to $301.00 and gave the stock an “equal weight” rating in a report on Tuesday, December 17th. Finally, Piper Sandler raised their price target on shares of Humana from $270.00 to $288.00 and gave the company a “neutral” rating in a report on Wednesday, January 15th. Nineteen investment analysts have rated the stock with a hold rating and five have given a buy rating to the company’s stock. Based on data from MarketBeat.com, Humana currently has an average rating of “Hold” and a consensus price target of $297.68.

Humana Stock Down 2.0 %

NYSE HUM opened at $274.06 on Monday. The stock’s 50-day moving average price is $274.21 and its 200-day moving average price is $298.14. The company has a market capitalization of $33.00 billion, a P/E ratio of 24.27, a price-to-earnings-growth ratio of 2.11 and a beta of 0.56. The company has a quick ratio of 1.76, a current ratio of 1.76 and a debt-to-equity ratio of 0.67. Humana Inc. has a 52 week low of $213.31 and a 52 week high of $406.46.

Insiders Place Their Bets

In other news, insider Timothy S. Huval sold 3,703 shares of the stock in a transaction on Tuesday, December 31st. The shares were sold at an average price of $256.26, for a total value of $948,930.78. Following the completion of the sale, the insider now directly owns 8,181 shares of the company’s stock, valued at $2,096,463.06. This represents a 31.16 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which is available at this hyperlink. 0.32% of the stock is owned by company insiders.

Humana Company Profile

Humana Inc, together with its subsidiaries, provides medical and specialty insurance products in the United States. It operates through two segments, Insurance and CenterWell. The company offers medical and supplemental benefit plans to individuals. It has a contract with Centers for Medicare and Medicaid Services to administer the Limited Income Newly Eligible Transition prescription drug plan program; and contracts with various states to provide Medicaid, dual eligible, and long-term support services benefits.